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Purpose: Intensity-modulated radiotherapy (IMRT) and helical tomotherapy (HT) have been adopted for radiotherapy
treatment of anal canal carcinoma (ACC) due to better conformality, dose homogeneity and normal-tissue sparing
compared to 3D-CRT. To date, only one published study compares dosimetric parameters of IMRT vs HT in ACC, but
there are no published data comparing toxicities. Our objectives were to compare dosimetry and toxicities between
these modalities.
Methods and materials: This is a retrospective study of 35 ACC patients treated with radical chemoradiotherapy at
two tertiary cancer institutions from 2008–2010. The use of IMRT vs HT was primarily based on center availability. The
majority of patients received fluorouracil (5-FU) and 1–2 cycles of mitomycin C (MMC); 2 received 5-FU and cisplatin.
Primary tumor and elective nodes were prescribed to ≥54Gy and ≥45Gy, respectively. Patients were grouped into two
cohorts: IMRT vs HT. The primary endpoint was a dosimetric comparison between the cohorts; the secondary endpoint
was comparison of toxicities.
Results: 18 patients were treated with IMRT and 17 with HT. Most IMRT patients received 5-FU and 1 MMC cycle, while
most HT patients received 2 MMC cycles (p < 0.01), based on center policy. HT achieved more homogenous coverage
of the primary tumor (HT homogeneity and uniformity index 0.14 and 1.02 vs 0.29 and 1.06 for IMRT, p = 0.01
and p < 0.01). Elective nodal coverage did not differ. IMRT achieved better bladder, femoral head and peritoneal
space sparing (V30 and V40, p≤ 0.01), and lower mean skin dose (p < 0.01). HT delivered lower bone marrow (V10,
p < 0.01) and external genitalia dose (V20 and V30, p < 0.01). Grade 2+ hematological and non-hematological
toxicities were similar. Febrile neutropenia and unscheduled treatment breaks did not differ (both p = 0.13),
nor did 3-year overall and disease-free survival (p = 0.13, p = 0.68).
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Conclusions: Chemoradiotherapy treatment of ACC using IMRT vs HT results in differences in dose
homogenity and normal-tissue sparing, but no significant differences in toxicities.
Keywords: Anal cancer, Tomotherapy, Intensity modulated radiotherapy, Dosimetry, ToxicitiesIntroduction
Since the 1980s, standard management of anal canal car-
cinoma (ACC) has been definitive chemoradiation therapy
(CRT), with salvage abdominal-perineal resection (APR)
for those who fail CRT [1-3]. Although CRT has been
demonstrated in several randomized controlled trials as
effective treatment for ACC, it is associated with signifi-
cant toxicities [4-6]. Treatment breaks in up to 40-50% of
patients have been reported due to hematological, derma-
tological and gastrointestinal toxicities [7,8]. Efforts have
been made to reduce toxicities through newer chemother-
apy regimens and radiotherapy (RT) techniques [9-11].
Development of more conformal RT techniques has re-
duced normal tissue toxicity and the need for unintended
treatment breaks [11].
RTOG 0529 demonstrated significantly lower hematological,
gastrointestinal and dermatological toxicities with intensity-
modulated radiotherapy (IMRT) compared to conventional
2D-planning in ACC treatment [12]. Helical tomotherapy
(HT) delivery, a newer RT technique, has shown improved
target conformality, dose homogeneity and normal-tissue
sparing compared to IMRT in other tumor sites [12,13].
In Alberta, use of IMRT vs HT is dependent on center
availability and preference. To date, only one published
study compares dosimetric parameters of IMRT vs HT
in ACC, but there are no published data comparing tox-
icities [14]. Our objectives were to compare dosimetry
and toxicities between these modalities.
Materials and methods
Patient population
This retrospective study included ACC patients treated
with definitive CRT between 2008–2010 at two provin-
cial tertiary cancer centers (Tom Baker Cancer Center
(TBCC) and Cross Cancer Institute (CCI)). Approval for
this study was obtained from the University of Calgary
Conjoint Health Research Ethics board.
Patients were included if they were ≥18 years of age,
had a histologic diagnosis of ACC, no other active malig-
nancies, and were treated with curative-intent CRT with a
primary planning target volume (PTVprimary) dose of 54–
55.4 Gy. All patients were treated with IMRT or HT, and
chemotherapy consisting of 2 cycles of 5-FU and 1–2 cy-
cles of mitomycin C (MMC) or cisplatin. Patients who
had metastatic disease, received PTVprimary dose <54 or
>55.4 Gy, RT alone, and RT treatment techniques other
than IMRT or HT were excluded.Pre-treatment evaluation of all patients included tumor
biopsy, clinical examination, baseline complete blood count
(CBC), and computed tomography (CT) abdomen and
pelvis. Tumor size was based on clinical exam (when doc-
umented) or imaging. Weekly CBC and toxicities (skin,
gastrointestinal, genitourinary) while on treatment were
graded using the RTOG acute scoring index [15]. All
blood counts were retrieved from the provincial clinical
database (Alberta Netcare) during CRT and up to four
weeks post last chemotherapy cycle. Hematological nadirs
were recorded and analyzed.
Volume definitions
Treatment plans were evaluated on an Eclipse workstation
(Eclipse™ v8.9, Varian Medical Systems, Palo Alto, CA)
without change to original planning target volumes delin-
eated by treating physicians. Gross tumor volume (GTV),
clinical target volume (CTV), planning target volume
(PTV) were contoured, following the RTOG 0529 proto-
col, with deviations, if necessary, based on clinical judg-
ment [11]. CTVprimary included the primary tumor and
involved lymph nodes >1 cm identified on CT imaging
and/or endoscopic ultrasound, plus a margin. CTVnodes
included regional lymph nodes at risk including peri-
rectal, internal iliac, external iliac, obturator, presacral and
inguinal lymph nodes. PTVprimary and PTVnode were gen-
erated with a uniform 1 cm margin around the CTVprimary
and CTVnode respectively.
Organs at risk (OARs) included the bladder, peritoneal
cavity, femoral heads, external genitalia (vulva in women,
penis and scrotum in men), skin and bone marrow.
These volumes were contoured on the existing plans.
OAR volume definitions were based on the RTOG 0529
protocol except for small bowel and iliac crests [11]. The
peritoneal cavity included large and small bowel from
the L4/5 junction to the level of the bladder dome, with
exclusion of named structures. In lieu of iliac crests,
bone marrow was delineated, consisting of the L5 verte-
bra, sacrum, and bilateral iliac crests. This was felt to
better reflect bone marrow dose from SPECT bone mar-
row imaging and IMRT bone marrow sparing studies
[16,17]. Skin was generated as a 5 mm thick layer of tis-
sue within the body contour, excluding PTV.
Plan evaluation
The homogeneity of each plan with respect to PTVprimary
and PTVnode was evaluated by the homogeneity (HI) and
Table 1 Baseline characteristics of ACC patients treated with chemoradiation by treatment cohort
Characteristic IMRT (N = 18) n (%) HT (N = 17) n (%) P-value*
Treatment center (TBCC/CCI) 18 (100%)/0 (0%) 0 (0%)/17 (100%) <0.001
Age, y (median(range)) 61 (45.1, 85.1) 52 (34.8, 69.7) 0.0045
Gender, (male/female) 6 (33.3%)/12 (66.7%) 4 (23.5%)/13 (76.5%) 0.71
Smoker 4 (22.2%) 11 (64.7%) 0.02
ECOG status
ECOG 0 4 (22.2%) 7 (41.2%) 0.29
ECOG ≥1 14 (77.8%) 10 (58.8%)
Histology
Squamous 17 (94.4%) 17 (100%) 1.00
Other 1 (5.6%) 0 (0%)
AJCC T-stage
1 1 (5.6%) 0 (0%) 1.00
2 8 (44.4%) 7 (41.2%)
3 7 (38.9%) 8 (47.1%)
4 2 (11.1%) 2 (11.8%)
AJCC N-stage
N0 14 (77.8%) 11 (64.7%) 1.00
N1-3 4 (23.2%) 6 (36.3%)
Pretreatment Blood Counts
(median(range))
Hb (g/dL) 124.5 (101, 156) 141 (101, 163) 0.10
WBC (x109/L) 7.8 (5.1, 14.3) 8.6 (5.2, 15.5) 0.70
Neutrophil (x109/L) 5.7 (2.8, 10.3) 6.3 (2.7, 11.3) 0.60
Platelet (x109/L) 287.5 (146, 525) 287 (167, 368) 0.96
RT dose to Primary Tumor, Gy 54 (54, 55.4) 54 (54, 54) 0.04
(median(range))
Chemotherapy
Cisplatin + 5FU 2 (11.1%) 0 (0%) <0.001
MMC 1 cycle + 5FU 16 (88.9%) 1 (5.9%)
MMC 2 cycles + 5FU 0 (0%) 16 (94.1%)
*Fisher exact testing used where any cell n < 5, otherwise Chi-square testing used.
Figure 1 Dose distribution for ACC treated with IMRT vs HT.
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Table 2 Dosimetric coverage of treatment volumes and OARs by treatment cohort
Parameter IMRT HT P-value*
Median (range), Mean Median (range), Mean
PTVprimary
HI 0.28 (0.10, 1.09), 0.51 0.14 (0.05, 0.36), 0.18 0.015
UI 1.06 (1.04, 1.52), 1.09 1.03 (1.01, 1.07), 1.03 <0.001
PTVnode
HI 0.42 (0.14, 1.25), 0.48 0.55 (0.33, 0.79), 0.54 0.06
UI 1.12 (1.04, 1.52), 1.16 1.17 (1.09, 1.21), 1.16 0.15
Bladder
V30 94 (51, 100), 88.8 100 (94, 100), 99 0.009
V40 56.5 (13, 92), 55.5 96 (44, 100), 90.9 <0.001
V50 14 (0.9, 54), 17.5 28 (0.2, 35), 21 0.37
Mean (Gy) 40.9 (32.4, 49.5), 41.3 47 (38.3, 49.2), 46.5 0.002
Median (Gy) 41.6 (30.3, 51.1), 41.5 47.1 (37.1, 49.0), 46.5 0.002
Bone Marrow
V10 82.5 (47, 98), 78.6 67 (63, 75), 67.4 0.007
V20 62.5 (22, 88), 60.9 56 (51, 60), 56 0.08
Mean (Gy) 27.6 (12.4, 37.4), 27.2 26.2 (23.1, 28.5), 26.3 0.39
Median (Gy) 29.4 (9.1, 44.3), 28.9 28.3 (21.1, 33.4), 28.3 0.81
Femoral heads
V30 68.5 (15, 99), 63.7 91 (76, 100), 90.3 <0.001
V40 14.5 (0, 50), 15.3 47 (27, 67), 50 <0.001
V50 0 (0, 14), 1.2 0 (0, 26), 3.1 0.94
Mean (Gy) 32 (23.5, 41.9), 31.5 38.9 (35.4, 44.1), 39.1 <0.001
Median (Gy) 32.7 (23.6, 40.2), 31.6 39.3 (35.2, 43.2), 39.8 <0.001
Peritoneal Cavity
V30 26.5 (0.1, 66), 30.7 46 (6, 76), 44.6 0.01
V40 11 (0.9, 53), 17.2 34 (2, 66), 32.5 0.003
V45 4.5 (0, 44), 9.2 22 (0.5, 57), 23.4 0.002
V50 0.9 (0, 17), 1.7 2 (0, 27), 4.1 0.01
Mean (Gy) 20.2 (4.7, 36.4), 20.4 26.3 (9, 40.6), 25.6 0.04
Median (Gy) 19.7 (2.3, 41.8), 19.3 26 (4.1, 45.7), 25.4 0.09
External Genitalia
V20 98.5 (62, 100), 91 73 (48, 98), 73.7 <0.001
V30 64 (19, 99), 65 25 (6, 58), 27.1 <0.001
V40 27 (0, 86), 25.7 5 (0, 48), 9.8 0.02
V50 2 (0, 44), 7.2 0.9 (0, 39), 4.4 0.11
Mean (Gy) 33.6 (21.8, 47.6), 33.6 25.1 (18, 38.9), 26 <0.001
Median (Gy) 33.3 (23.9, 48.9), 33.6 23.4 (18.9, 35.2), 24 <0.001
Skin
Mean (Gy) 17 (1.4, 21.3), 16 23.1 (11.2, 26.8), 22 <0.001
Median (Gy) 15.9 (11.9, 19.2), 15.9 20.4 (6, 23.4), 19.1 <0.001
*Mann–Whitney test reported.
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tween Dmax and Dmin divided by the prescription dose,
while UI was D5/D95. A value approaching 0 for HI and
unity for UI indicates optimal dose homogeneity [18,19].
For OARs, median and mean dose were reported. In
addition, V30, V40, and V50 were recorded for the femoral
heads, bladder and peritoneal cavity. For external genitalia,
V20, V30, and V40 were recorded while V10 and V20
were recorded for bone marrow.
Statistical analysis
Patients were classified into two treatment cohorts: IMRT
vs HT. A dosimetric comparison of plan homogeneity
and OARs was performed. Disease-free survival (DFS),
overall survival (OS), colostomy-free survival (CFS) and
acute hematological and non-hematological toxicities were
analyzed.
DFS was the interval between diagnosis and evidence
of local, regional or metastatic failure, second primary,
death or last follow-up for patients who did not fail.
Local failure was evidence of persistent local disease or
local recurrence. Regional failure was persistence, ap-
pearance or recurrence of regional nodal disease. Pa-
tients with persistent disease were considered as failing
on the day of their first follow-up post CRT or date of
biopsy-proven persistent disease (when available). Failure
for OS was death due to any cause and was measured
from diagnosis to the date of death or last follow-up.
CFS was the interval between diagnosis and date of col-
ostomy, including diverting colostomy and colostomy
from salvage APR, or last follow-up for those not requir-









Febrile neutropenia requiring hospitalization 5 (14.3)
Grade 2+ Non-Hematologic Toxicities†
Skin 29 (82.9)
Upper GI 9 (25.7)
Lower GI 18 (51.4)
GU 3 (8.6)
Unscheduled treatment break 8 (22.9)
*Fisher exact testing used where any cell n < 5, otherwise Chi-square testing used.
†RTOG acute radiation morbidity scoring criteria [17].Results were analyzed with STATA Version 12.0 for
Microsoft Windows (StataCorp LP, College Station, Texas).
Chi-squared or Fisher exact testing was used to test differ-
ences between discontinuous variables. Wilcoxon rank-sum
testing was used to test differences between continu-
ous variables. DFS, OS, and CFS were analyzed using
Kaplan-Meier survival analyses with log rank testing.
P values of <0.05 were considered statistically significant.
Results
Demographics
72 patients were diagnosed with ACC in Alberta be-
tween 2008–2010. Thirty-seven patients were excluded
from the analysis (13 treated with a technique other than
IMRT or HT, 7 received RT alone, 1 was treated with sur-
gery alone, 1 had metastatic disease at diagnosis, 13 re-
ceived a dose PTVprimary <54 Gy or >55.4 Gy, and 2 with
missing data). Of the remaining 35 patients, 18 patients
were treated with IMRT (all treated at TBCC) and 17 with
HT (all treated at CCI). Patients treated with HT were
treated on TomoTherapy® Hi-Art® system, version 2.2.4.1
(Accuray, Inc, Sunnyvale, CA). Patients treated with IMRT
were treated on, Clinac 21EX, Clinac IX, or Triology
(Varian Medical, Palo Alto, CA). Patient, tumor and treat-
ment characteristics are summarized in Table 1.
Both groups were balanced in regards to performance
status, histology, T stage, N stage, and pre-treatment
hematological parameters. The IMRT group had slightly
older patients (p = 0.0045) and fewer smokers (p = 0.02).
The median RT dose was the same between the groups,
but dose was more variable in the IMRT group. Chemo-
therapy regimen was significantly different, with 16 patientsoradiation by treatment cohort
IMRT HT P-value*
(N = 18) (N = 17)
n (%) n (%)
13 (72.2) 14 (82.4) 0.69
10 (55.6) 12 (70.6) 0.36
6 (33.3) 7 (41.2) 0.63
5 (27.8) 6 (35.3) 0.63
1 (5.6) 4 (23.5) 0.18
14 (77.8) 15 (88.2) 0.66
6 (33.3) 3 (17.7) 0.44
12 (66.7) 6 (35.3) 0.06
2 (11.1) 1 (5.9) 1.00
6 (33.3) 2 (11.8) 0.23
Figure 2 Survival analysis of ACC patients treated with
chemoradiotherapy by treatment cohort. A. Overall Survival.
B. Disease-Free Survival. C. Colostomy-Free Survival.
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16 patients in the HT group receiving 2 MMC cycles with
5-FU (p < 0.001).
Dosimetric outcomes
Figure 1 shows a typical dose distribution on axial imaging
at the level of PTVprimary for IMRT and HT techniques.
Table 2 details the dosimetric coverage of treatment vol-
umes and OARs by cohort. The HT group achieved more
homogenous PTVprimary coverage compared to IMRT (HI
p = 0.015, UI p < 0.001). PTVnodes coverage did not differ
between the techniques, although HI approached signifi-
cance (p = 0.06). IMRT achieved better bladder, peritoneal
space and femoral head sparing (V30 and V40, p ≤ 0.01).
Median and mean skin dose was also lower with IMRT
(p < 0.001). HT delivered lower dose to bone marrow
(V10, p < 0.01) and external genitalia (V20 and V30,
p < 0.001). A dosimetry model was constructed containing
the factors of HI and UI for PTVprimary and HI for
PTVnodes. No factor was significant for either outcome on
multivariate analysis.
Toxicities
Acute hematological and non-hematological toxicities are
presented in Table 3. The most common toxicities were
leukopenia and skin reaction. Grade 2+ hematological and
non-hematological toxicities were similar between the
groups. There were no significant differences in lower or
upper gastrointestinal, genitourinary and skin toxicities.
Additionally, febrile neutropenia and unscheduled treat-
ment breaks did not differ between the two groups.
Overall survival, disease-free survival and colostomy-free
survival
Median follow-up for survivors at the time of analysis
was 23.7 months. Estimated 3-year OS (IMRT 87.1% vs
HT 100%, p = 0.13, Figure 2A) and DFS (IMRT 32.9% vs
HT 51.8%, p = 0.68, Figure 2B) by Kaplan Meier analysis
were similar between the two groups. Estimated 3-year
CFS was also similar (IMRT 57.3% vs HT 70.2%, p = 0.29,
Figure 2C).
Multivariate analysis was not performed on OS, due to
the small number of events. Multivariate analysis for DFS
and CFS outcomes was limited to 3 factors per model, ac-
counting for the number of events. For each outcome, a
demographics model consisting of age, smoking status,
and treatment group was constructed. No factor was sig-
nificant for either outcome.
Discussion
Advances in CRT for ACC have focused on toxicity reduc-
tion by alterations in chemotherapy regimens and radio-
therapy delivery [9-11]. Large retrospective studies have
shown promising results with cisplatin-based regimenscompared to standard MMC treatment [20,21]. However,
two recent phase III trials, RTOG 98–11 and ACTII, failed
to demonstrate superiority of cisplatin to MMC for ACC
treatment [9,10]. As such, ACC treatment with MMC and
5-FU remains standard of care.
Development of more conformal RT techniques has
resulted in reduced normal-tissue toxicity. RTOG 0529
established superiority of IMRT to conventional 2D-
planning in ACC treatment, with significant reduction in
Yeung et al. Radiation Oncology  (2015) 10:92 Page 7 of 8grade 2+ hematological, and grade 3+ gastrointestinal
and dermatological toxicities using IMRT [11]. Newer RT
techniques, such as HT, have shown improved target con-
formality, dose homogeneity and normal-tissue sparing
compared to IMRT [12,13]. To date, there is only one
study by Joseph et al. comparing dosimetry between HT
and IMRT in ACC treatment [14]. Our current retrospect-
ive study serves as the first study comparing toxicities in
ACC treatment between these two techniques.
Seventy-two patients were diagnosed with ACC be-
tween our study period, but less than half of the patients
were included in the current analysis. The majority of
exclusions were based on RT technique and PTVprimary
dose outside of 54–55.4 Gy, in an effort to maintain
consistency in dose and treatment volumes. Chemother-
apy was significantly different, with the majority of
IMRT patients receiving 1 MMC cycle, versus 2 cycles
in the HT group. Historically, patients treated at the cen-
ter where HT is available have been treated with 2
MMC cycles due to physician preference, versus 1 MMC
cycle at the center where only IMRT is available.
Similar to the dosimetric study by Joseph et al., HT in
our study achieved superior target conformality com-
pared to IMRT for PTVprimary coverage [14]. OAR dose
constraints in our study reflect those in RTOG 0529,
with the exception of peritoneal cavity and bone marrow
[11]. In both the current study and the previous study
by Joseph et al., IMRT achieved better sparing of bilateral
femoral heads, while HT delivered lower dose to external
genitalia. However, in our study, IMRTalso achieved lower
bladder, peritoneal cavity and skin doses, while Joseph
et al. reported improvement in sparing of bladder and
peritoneal cavity with HT. In addition, our study demon-
strated better bone marrow and external genitalia sparing
with HT [14].
Differences in dose distribution and sparing of OARs
between the two studies may be secondary to differences
in calculation algorithms and study design. Although we
found a significant difference between skin dose for IMRT
and HT, it is known that there are large uncertainties in
calculated skin dose for both the Eclipse analytic aniso-
tropic algorithm and HT dose calculation algorithms
[22,23]. Furthermore, the planning study by Joseph et al.
generated HT and IMRT plans on the same patients,
thereby minimizing anatomical variations between the
two groups. There was also strict adherence to contouring
and planning guidelines [14]. Our study, on the other
hand, is retrospective with a larger sample of patients, and
reflects real practice in a more generalized population.
Despite significant differences in OAR doses and chemo-
therapy regimens, acute hematological and non-hematological
toxicities were similar between the groups. Three-year OS,
DFS and CFS Kaplan Meier estimates were also similar.
A recent retrospective study by our group suggestsreduction of grade 3+ hematological and skin toxicities
with 1 MMC cycle versus 2 cycles in ACC treatment,
without compromise to OS, CFS and DFS [24]. Potential
differences in acute toxicities secondary to different
chemotherapy regimens may have been mitigated by
radiotherapy technique. Further studies with more bal-
anced groups in regards to chemotherapy may assist in
confirming this hypothesis and our current results.
This study has inherent limitations of a retrospective
study from a single health authority. Despite utilizing a
standardized toxicity grading scale, potential subjectivity
exists in retrospectively grading toxicities. In effort to
obtain consistency, a single reviewer graded all toxicities.
Conclusions
In our analysis of IMRT vs HT in ACC, differences in dose
homogeneity and normal-tissue sparing were observed,
but there were no significant differences in toxicities. Fur-
ther investigation to increase cohort patient numbers
should be performed, to definitively determine the impact
of these techniques on toxicities and outcomes.
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